<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Maximizing Imerys PCC from Mexico: Value, Competition, and Growth Scenarios</title>
<style>
body {
font-family: Arial, sans-serif;
margin: 0;
padding: 0;
background-color: #f4f4f4;
}
.slide {
max-width: 800px;
margin: 20px auto;
padding: 20px;
background-color: white;
border: 1px solid #ddd;
border-radius: 8px;
box-shadow: 0 2px 4px rgba(0,0,0,0.1);
}
.slide h1 {
color: #333;
border-bottom: 2px solid #eee;
padding-bottom: 10px;
}
.slide h2 {
color: #555;
margin-top: 20px;
}
.slide ul {
list-style-type: disc;
margin-left: 20px;
}
.slide p {
line-height: 1.6;
}
.visuals, .notes {
background-color: #f9f9f9;
padding: 10px;
border-left: 4px solid #ccc;
margin-top: 10px;
}
.references {
font-size: 0.8em;
color: #888;
}
</style>
</head>
<body>
<div class="slide">
<h1>Slide 1: Title Slide</h1>
<h2>Title: Maximizing Imerys PCC from Mexico: Value, Competition, and Growth Scenarios</h2>
<p>Subtitle: Focus on Pharma, Paints & Coatings, and Calcium Citrate Opportunities</p>
<p>Additional Elements: Presenter name, July 11, 2025, Imerys logo.</p>
<div class="visuals">
<p>Visuals: Background map of Mexico with PCC plant icons.</p>
</div>
<div class="notes">
<p>Notes: Hook: “With a max capacity of 12k MT, Imerys’ Mexican PCC is poised for high-margin growth—let’s explore the strategies.”</p>
</div>
</div>

<div class="slide">
<h1>Slide 2: Agenda</h1>
<h2>Key Content:</h2>
<ul>
<li>Imerys PCC Value Proposition</li>
<li>North America Competitive Landscape</li>
<li>Global Competitive Landscape</li>
<li>Prices and Key Competitors</li>
<li>Scenario 1: Growing the Pharma Market</li>
<li>Scenario 2: Slurry Blends for Paints & Coatings</li>
<li>Scenario 3: Developing Calcium Citrate</li>
<li>Comparative Analysis and Recommendations</li>
</ul>
<div class="visuals">
<p>Visuals: Vertical timeline with icons (e.g., graph for landscapes, lightbulb for scenarios).</p>
</div>
<div class="notes">
<p>Notes: “We’ll use data-driven charts to highlight opportunities.”</p>
</div>
</div>

<div class="slide">
<h1>Slide 3: Imerys PCC Value Proposition</h1>
<h2>Key Content:</h2>
<ul>
<li>High Purity & Customization: >99% purity, tailored particle sizes for superior performance in pharma, paints, and beyond.</li>
<li>Mexico Advantages: Proximity to NA markets (USMCA-enabled, 5-10% logistics savings), local limestone for cost efficiency.</li>
<li>Sustainability: 24% GHG reduction (2021-2023), enabling eco-friendly solutions.</li>
<li>Overall: Premium functional additive reducing customer costs (e.g., TiO2 extender in paints) while boosting opacity, rheology, and bioavailability.</li>
</ul>
<div class="visuals">
<p>Visuals: Infographic quadrants with icons; pie chart: Value Breakdown (40% Performance, 30% Cost Savings, 20% Sustainability, 10% Reliability).</p>
</div>
<div class="notes">
<p>Notes: “This positions PCC as a high-value alternative to GCC, with Mexican production enhancing regional appeal.” <span class="references">60 63</span></p>
</div>
</div>

<div class="slide">
<h1>Slide 4: North America Competitive Landscape</h1>
<h2>Key Content:</h2>
<ul>
<li>Market Size: NA Calcium Carbonate ~$5-6B in 2025; PCC subset ~$1-2B, growing at 5-7% CAGR.</li>
<li>Key Drivers: Demand in paper (40%), plastics (25%), pharma/paints (20%); urbanization and sustainability push.</li>
<li>Competitors: Imerys (strong in customization), MTI (acquired Mexican plant), Omya (volume leader), Huber (specialty grades).</li>
<li>Imerys Edge: Regional capacity expansion (2022), integrated minerals for blends.</li>
</ul>
<div class="visuals">
<p>Visuals: Pie chart: NA Market Share (Imerys 20%, MTI 25%, Omya 30%, Others 25%). Bar chart: Growth Rates (PCC 6%, GCC 4%).</p>
</div>
<div class="notes">
<p>Notes: “NA landscape favors local producers like Imerys amid tariffs and supply chain focus.” <span class="references">4 5 8 1 60</span></p>
</div>
</div>

<div class="slide">
<h1>Slide 5: Global Competitive Landscape</h1>
<h2>Key Content:</h2>
<ul>
<li>Market Size: Global PCC ~$2.2-5.6B in 2025, projected to $3-8B by 2030-34 at 4-7% CAGR.</li>
<li>Key Regions: Asia-Pacific (50% share, low-cost production), Europe (innovation hub), NA (premium demand).</li>
<li>Competitors: Omya (global leader), MTI, Imerys (top 3, sustainability focus), Chinese suppliers (price-competitive but quality variable).</li>
<li>Trends: Shift to sustainable PCC; tariffs impacting imports (e.g., US on China).</li>
<li>Imerys Position: 10-15% global share, leveraging Mexico for NA exports.</li>
</ul>
<div class="visuals">
<p>Visuals: World map with bubbles (size by market value: APAC largest); line chart: Global PCC Growth (2025-2030, CAGR lines for regions).</p>
</div>
<div class="notes">
<p>Notes: “Global competition is intense, but Imerys’ quality and ESG differentiate it.” <span class="references">25 26 27 29 32 33</span></p>
</div>
</div>

<div class="slide">
<h1>Slide 6: Prices and Competitors</h1>
<h2>Key Content:</h2>
<ul>
<li>PCC Prices (2025 Avg.): Industrial $300-500/MT; Pharma $500-1,200/MT; Slurries $400-800/MT.</li>
<li>Competitors’ Pricing: Omya/MTI similar ($350-600/MT base); Chinese lower ($200-400/MT) but tariffs add 10-20%.</li>
<li>Calcium Citrate: Market $0.92B in 2025; prices $1,000-2,000/MT (premium over PCC).</li>
<li>Imerys Opportunity: Premium pricing for blends/custom (15-30% markup).</li>
</ul>
<div class="visuals">
<p>Visuals: Bar chart: Price Comparison (Imerys PCC $450/MT avg., Omya $420, MTI $460, Chinese $300); stacked bar for segments (pharma highest).</p>
</div>
<div class="notes">
<p>Notes: “Imerys can command premiums in high-value segments.” <span class="references">15 22 40 42 53</span></p>
</div>
</div>

<div class="slide">
<h1>Slide 7: Scenario Overview</h1>
<h2>Key Content:</h2>
<ul>
<li>Assumptions: Fixed cost $300/MT; max capacity 12k MT/year; full utilization; 5-year projection.</li>
<li>Focus: Revenue, margins, market growth alignment.</li>
<li>Goal: Identify highest-profit path.</li>
</ul>
<div class="visuals">
<p>Visuals: Table: Scenario Summary (Price/MT, Margin %, Total Profit at Max Cap.).</p>
</div>
<div class="notes">
<p>Notes: “All scenarios assume same costs; differences in pricing drive margins.”</p>
</div>
</div>

<div class="slide">
<h1>Slide 8: Scenario 1 - Grow the Pharma Market</h1>
<h2>Key Content:</h2>
<ul>
<li>Strategy: Certify GMP, partner with pharma firms; target supplements/antacids (4-6% CAGR).</li>
<li>Advantages: High purity for bioavailability; NA demand growth.</li>
<li>Price: $700/MT (premium grade); Margin: 57% ($400/MT profit).</li>
<li>At Max Cap: Revenue $8.4M; Profit $4.8M/year.</li>
</ul>
<div class="visuals">
<p>Visuals: Line chart: Revenue Projection (Year 1: $8.4M at full cap; 5-year cumulative $42M, with 5% annual growth).</p>
</div>
<div class="notes">
<p>Notes: “Pharma offers steady, high-margin growth.” <span class="references">15 17 23</span></p>
</div>
</div>

<div class="slide">
<h1>Slide 9: Scenario 2 - Slurry Blends for Paints & Coatings</h1>
<h2>Key Content:</h2>
<ul>
<li>Strategy: Blend PCC slurry (60% solids) with Imerys minerals (DE/wollastonite); target architectural/industrial (4-5% CAGR).</li>
<li>Advantages: Enhanced opacity/durability; TiO2 extender for 10-15% cost savings.</li>
<li>Price: $500/MT (value-added blend); Margin: 40% ($200/MT profit).</li>
<li>At Max Cap: Revenue $6M; Profit $2.4M/year.</li>
</ul>
<div class="visuals">
<p>Visuals: Bar chart: Performance Metrics (Opacity +20%, Cost Savings 15% vs. standalone); revenue bar vs. base PCC.</p>
</div>
<div class="notes">
<p>Notes: “Blends leverage existing portfolio for competitive edges.” <span class="references">50 51 53</span></p>
</div>
</div>

<div class="slide">
<h1>Slide 10: Scenario 3 - Develop Calcium Citrate Product</h1>
<h2>Key Content:</h2>
<ul>
<li>Strategy: Convert PCC to calcium citrate (via citric acid reaction); grow in supplements/food (3-5% CAGR).</li>
<li>Advantages: Higher bioavailability than carbonate; enter $0.92B market.</li>
<li>Price: $1,200/MT (premium derivative); Margin: 75% ($900/MT profit).</li>
<li>At Max Cap: Revenue $14.4M; Profit $10.8M/year.</li>
</ul>
<div class="visuals">
<p>Visuals: Area chart: Market Penetration (Start 5% share in NA; grow to 15% over 5 years, revenue to $72M cumulative).</p>
</div>
<div class="notes">
<p>Notes: “This diversification yields the highest margins but requires R&D investment.” <span class="references">39 40 42 44</span></p>
</div>
</div>

<div class="slide">
<h1>Slide 11: Comparative Analysis of Scenarios</h1>
<h2>Key Content:</h2>
<ul>
<li>Scenario 1 (Pharma): Balanced growth, medium risk.</li>
<li>Scenario 2 (Slurries): Lowest margin but easiest integration.</li>
<li>Scenario 3 (Citrate): Highest profit potential, innovation-driven.</li>
<li>Recommendation: Prioritize Scenario 3 for max returns ($10.8M profit/year at cap).</li>
</ul>
<div class="visuals">
<p>Visuals: Stacked bar chart: Annual Profit at Max Cap (Sc1: $4.8M, Sc2: $2.4M, Sc3: $10.8M); radar chart: Scenario Strengths (Margin, Risk, Growth).</p>
</div>
<div class="notes">
<p>Notes: “Scenario 3 maximizes value from capacity.”</p>
</div>
</div>

<div class="slide">
<h1>Slide 12: Risks and Mitigations</h1>
<h2>Key Content:</h2>
<ul>
<li>Risks: Raw material volatility, competition, regulatory hurdles (e.g., FDA for citrate).</li>
<li>Mitigations: Diversify suppliers, invest in R&D, leverage Mexico’s stability.</li>
</ul>
<div class="visuals">
<p>Visuals: Risk matrix (High/Med/Low for each scenario).</p>
</div>
<div class="notes">
<p>Notes: “Proactive strategies ensure resilience.”</p>
</div>
</div>

<div class="slide">
<h1>Slide 13: Recommendations and Next Steps</h1>
<h2>Key Content:</h2>
<ul>
<li>Pursue Scenario 3 with pilots; allocate 20% capacity to each initially.</li>
<li>Invest: $5M in R&D/blending tech.</li>
<li>Timeline: Pharma growth Q3 2025; slurries Q4; citrate dev 2026.</li>
</ul>
<div class="visuals">
<p>Visuals: Gantt chart: Implementation Timeline (2025-2030).</p>
</div>
<div class="notes">
<p>Notes: “Actionable steps to capture $10M+ annual profits.”</p>
</div>
</div>

<div class="slide">
<h1>Slide 14: Q&A</h1>
<h2>Key Content:</h2>
<p>Open for questions.</p>
<div class="visuals">
<p>Visuals: Contact info, thank you graphic.</p>
</div>
<div class="notes">
<p>Notes: “Let’s discuss how to implement.”</p>
</div>
</div>

<div class="slide">
<h1>Slide 15: References</h1>
<h2>Key Content:</h2>
<p>List sources (e.g., Market.us, Fortune Business Insights, Imerys reports).</p>
<div class="visuals">
<p>Visuals: Bullet list.</p>
</div>
<div class="notes">
<p>Notes: “Data from July 2025 searches.”</p>
</div>
</div>
</body>
</html>